Cyrano Therapeutics Announces CYR-064 Phase 2 FLAVOR Trial Results to be Featured at the 72nd Annual Meeting of the American Rhinologic Society

Oral presentation to highlight Phase 2 data evaluating CYR-064 for persistent post-viral loss of smell DELRAY BEACH, Fla., July 29, 2026 /PRNewswire/ -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company developing novel treatments for smell and taste disorders,...